
Current Price | $8.38 | Mkt Cap | $519.8M |
---|---|---|---|
Open | $8.21 | P/E Ratio | 10.51 |
Prev. Close | $8.38 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.91 - $8.40 | Volume | 580,810 |
52-Wk Range | $4.29 - $8.40 | Avg. Daily Vol. | 622,139 |
Current Price | $8.38 | Mkt Cap | $519.8M |
---|---|---|---|
Open | $8.21 | P/E Ratio | 10.51 |
Prev. Close | $8.38 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.91 - $8.40 | Volume | 580,810 |
52-Wk Range | $4.29 - $8.40 | Avg. Daily Vol. | 622,139 |
The best Bull and Bear pitches based on recency and number of recommendations.
MacroGenics seems to be a little more substantial than the other 2013 biopharma IPO's I've recently been catching up on. The company matured their platforms and advanced their pipeline for thirteen years before going public, with the result that the… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about MGNX.
Recs
MacroGenics stock up 110% after announcing positive Phase 3 trial results
Published: Feb 6, 2019 8:57 a.m. ET
By
Sarah
Toy
Reporter
Shares of biotech MacroGenics Inc. MGNX, +143.02% shot up 110% in premarket trade Wednesday after the company announced that the Phase 3 trial of potential breast cancer treatment margetuximab met its primary endpoint. Margetuximab is the company's monoclonal antibody aimed at treating later-stage breast cancer patients who test positive for a protein called human epidermal growth factor receptor 2, or HER-2. A gene mutation that makes an excess of the HER-2 protein is present in about 15% of primary invasive breast cancers, according to UpToDate, an evidence-based medical resource used by clinicians. This particular trial showed longer progression-free survival in patients treated with a combination of margetuximab and chemotherapy compared to those on trastuzumab (brand name Herceptin) and chemotherapy, a standard-of-care treatment. The company also said approximately 85% of patients in the study were carriers of the CD16A 158F allele, a gene variation has been associated with a reduced clinical response to Herceptin and other antibodies. MacroGenics said it plans to submit a biologics license application to the U.S. Food and Drug Administration in the second half of 2019. Shares of MacroGenics have fallen 13% in the year to date, while the S&P 500 SPX, -0.42% has gained 9.2%.
Recs
Big pipeline
Recs
I'm in on this one.
Find the members with the highest scoring picks in MGNX.
biotechf (40.98) Score: +200.40
The Score Leader is the player with the highest score across all their picks in MGNX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
biotechf | 40.98 | 2/8/2016 |
![]() |
5Y | $17.91 | -53.27% | +147.13% | +200.40 | 0 Comment | |
chushogi | 55.12 | 12/16/2016 |
![]() |
5Y | $19.68 | -57.47% | +103.13% | +160.60 | 0 Comment | |
![]() |
chrispycrunch | 68.49 | 2/6/2019 |
![]() |
5Y | $25.64 | -67.36% | +68.30% | +135.65 | 0 Comment |
Playa17 | < 20 | 10/5/2022 |
![]() |
5Y | $3.61 | +131.86% | +22.95% | +108.90 | 0 Comment | |
cubswin08 | 56.73 | 5/6/2020 |
![]() |
5Y | $16.20 | -48.33% | +60.35% | +108.68 | 0 Comment | |
Playa14 | < 20 | 8/16/2022 |
![]() |
5Y | $4.96 | +68.75% | +7.33% | +61.42 | 0 Comment | |
Under5b | < 20 | 9/15/2023 |
![]() |
5Y | $4.88 | +71.52% | +2.23% | -69.28 | 0 Comment | |
itainvestor | 30.42 | 8/2/2021 |
![]() |
5Y | $25.87 | -67.65% | +4.22% | -71.87 | 0 Comment | |
portefeuille3 | 91.60 | 12/27/2017 |
![]() |
5Y | $19.35 | -56.74% | +71.66% | -128.40 | 0 Comment | |
TMFGBudwell | < 20 | 2/6/2019 |
![]() |
5Y | $25.00 | -66.52% | +68.40% | -134.92 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.